Transcutaneous auricular vagus nerve stimulation to acutely reduce emotional vulnerability and improve emotional regulation in borderline personality disorder (tVNS-BPD): study protocol for a randomized, single-blind, sham-controlled trial.

Publication date: Jun 19, 2024

Borderline personality disorder (BPD) is considered a disorder of emotion regulation resulting from the expression of a biologically determined emotional vulnerability (that is, heightened sensitivity to emotion, increased emotional intensity/reactivity, and a slow return to emotional baseline) combined with exposure to invalidating environments. Vagal tone has been associated with activity in cortical regions involved in emotion regulation and a lower resting state of vagal tone has been observed in BPD patients relative to healthy controls. Non-invasive transcutaneous auricular vagus nerve stimulation (taVNS) has been shown to reduce temper outbursts in adults with Prader-Willi Syndrome, to enhance recognition of emotions in healthy students, and to improve depressive and anxiety symptoms. Furthermore, a single session of taVNS has been shown to acutely alter the recognition of facial expressions of negative valence in adolescents with MDD and increase emotion recognition in controls. However, the effect of taVNS on emotional vulnerability and regulation in individuals diagnosed with BPD has not been investigated. Our aims are to determine if taVNS is effective in acutely reducing emotional vulnerability and improve emotional regulation in BPD patients. Forty-two patients will be randomized to a single session of taVNS or sham-taVNS while going through an affect induction procedure. It will consist of the presentation of one neutral and three negative affect-evoking 4-min-long videos in sequence, each of which is followed by a 4-min post-induction period during which participants will rate the quality and intensity of their current self-reported emotions (post-induction ratings) and the perceived effectiveness in managing their emotions during the video presentation. The rating of the current self-reported emotions will be repeated after every post-induction period (recovery ratings). Mixed models with individuals as random effect will be used to investigate the ratings at each stage of the study, taking into account the repeated measures of the same individuals at baseline, pre-induction, post-induction, and recovery. The study has potential to yield new insights into the role of vagal tone in emotion dysregulation in BPD and offer preliminary data on the effectiveness of taVNS as a possible non-invasive brain stimulation to treat a core symptom of BPD. ClinicalTrials. gov NCT05892900. Retrospectively registered on Jun 07, 2023.

Open Access PDF

Concepts Keywords
Clinicaltrials Borderline personality disorder
Depressive Emotion regulation
Healthy Emotional vulnerability
Nct05892900
Stage

Semantics

Type Source Name
disease MESH borderline personality disorder
disease MESH Prader-Willi Syndrome
disease MESH facial expressions
pathway REACTOME Reproduction
disease MESH personality disorder
disease MESH mental disorder
drug DRUGBANK Trestolone
disease MESH pus
drug DRUGBANK Isoxaflutole
disease MESH impulsivity
drug DRUGBANK Esomeprazole
disease MESH treatment resistant depression
disease MESH ganglion
disease MESH major depressive disorder
drug DRUGBANK gamma-Aminobutyric acid
drug DRUGBANK Sertraline
drug DRUGBANK Coenzyme M
disease MESH epilepsy
disease MESH seizure
disease MESH tinnitus
disease MESH schizophrenia
disease MESH chronic pain
disease MESH migraine
drug DRUGBANK Indoleacetic acid
disease MESH PTSD
disease MESH nasopharyngitis
disease MESH neurological disorder
disease MESH stroke
disease MESH cerebral aneurysm
drug DRUGBANK Trihexyphenidyl
drug DRUGBANK Profenamine
disease MESH Huntington’s chorea
disease MESH multiple sclerosis
disease MESH delirium
disease MESH dementia
disease MESH syndrome
disease MESH autism spectrum disorder
disease MESH ADHD
drug DRUGBANK Ethanol
drug DRUGBANK Cocaine
drug DRUGBANK Amphetamine
drug DRUGBANK Benzodiazepine
drug DRUGBANK Carbamazepine
drug DRUGBANK Gabapentin
drug DRUGBANK Lamotrigine
drug DRUGBANK Levetiracetam
drug DRUGBANK Pregabalin
drug DRUGBANK Topiramate
drug DRUGBANK Tretamine
disease MESH aneurysm
disease MESH psychotic disorder
disease MESH violence
disease MESH asthma
pathway KEGG Asthma
disease MESH atrial fibrillation
disease MESH autism
disease MESH cognitive impairment
disease MESH Crohn’s disease
disease MESH fibromyalgia
disease MESH inflammation
disease MESH sleep disorders
disease MESH death
disease MESH domestic violence
disease MESH emergency
drug DRUGBANK Nicotine
drug DRUGBANK Caffeine
disease MESH bipolar disorder
disease MESH loneliness
drug DRUGBANK Corticorelin
drug DRUGBANK Etoperidone
disease MESH Affective Disorders
disease MESH drug abuse
drug DRUGBANK 7-Methyl-Gpppa
drug DRUGBANK Vorinostat
disease MESH comorbidity
disease MESH hypersensitivity
disease MESH childhood trauma
disease MESH Chronic Conditions
disease MESH drug resistant epilepsy
drug DRUGBANK Tropicamide
disease MESH anxiety disorders

Original Article

(Visited 3 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *